WO2007079317A3 - Utilisation d’hypno-sedatifs pour traiter l’obesite ou maintenir la perte de poids - Google Patents
Utilisation d’hypno-sedatifs pour traiter l’obesite ou maintenir la perte de poids Download PDFInfo
- Publication number
- WO2007079317A3 WO2007079317A3 PCT/US2006/061679 US2006061679W WO2007079317A3 WO 2007079317 A3 WO2007079317 A3 WO 2007079317A3 US 2006061679 W US2006061679 W US 2006061679W WO 2007079317 A3 WO2007079317 A3 WO 2007079317A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treating obesity
- weight loss
- maintaining weight
- sedative hypnotics
- administering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Child & Adolescent Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L’invention concerne un procédé et des thérapies associées pour traiter l’obésité ou un trouble de l’alimentation associé en administrant un composé actif du récepteur GABA-A, tel qu’un hypno-sédatif, seul ou en combinaison avec un autre hypno-sédatif ou un agent anti-obésité. Spécifiquement, l’invention concerne un procédé pour traité l’obésité ou un trouble de l’alimentation associé en administrant de l’indiplon.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74275105P | 2005-12-06 | 2005-12-06 | |
US60/742,751 | 2005-12-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007079317A2 WO2007079317A2 (fr) | 2007-07-12 |
WO2007079317A3 true WO2007079317A3 (fr) | 2007-09-07 |
Family
ID=38141425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/061679 WO2007079317A2 (fr) | 2005-12-06 | 2006-12-06 | Utilisation d’hypno-sedatifs pour traiter l’obesite ou maintenir la perte de poids |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007079317A2 (fr) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999066919A1 (fr) * | 1998-06-19 | 1999-12-29 | Mcneil-Ppc, Inc. | Preparation pharmaceutique contenant un sel d'acetaminophene et au moins un autre principe actif |
US20050182268A1 (en) * | 2004-02-13 | 2005-08-18 | Jean-Claude Souvie | Process for the synthesis of (7-methoxy-3, 4-dihydro-1-naphthalenyl) acetonitrile and its application in the synthesis of agomelatine |
US20050234093A1 (en) * | 2003-06-25 | 2005-10-20 | H. Lundbeck A/S | Treatment of depression and other affective disorders |
FR2869542A1 (fr) * | 2004-04-29 | 2005-11-04 | Marie Madeleine Jeannet Gagnon | Traitement medical destine a faciliter la perte de poids et l'affinement localise (communement appele "cellulite") |
WO2006105455A2 (fr) * | 2005-03-31 | 2006-10-05 | Phase 2 Discovery | Methodes de traitement utilisant certains derives de melatonine |
WO2006133543A1 (fr) * | 2005-06-17 | 2006-12-21 | Everslim Formulations Ltd. | Suppléments alimentaires pour perte de poids, énergie durant la journée et relaxation la nuit |
-
2006
- 2006-12-06 WO PCT/US2006/061679 patent/WO2007079317A2/fr active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999066919A1 (fr) * | 1998-06-19 | 1999-12-29 | Mcneil-Ppc, Inc. | Preparation pharmaceutique contenant un sel d'acetaminophene et au moins un autre principe actif |
US20050234093A1 (en) * | 2003-06-25 | 2005-10-20 | H. Lundbeck A/S | Treatment of depression and other affective disorders |
US20050182268A1 (en) * | 2004-02-13 | 2005-08-18 | Jean-Claude Souvie | Process for the synthesis of (7-methoxy-3, 4-dihydro-1-naphthalenyl) acetonitrile and its application in the synthesis of agomelatine |
FR2869542A1 (fr) * | 2004-04-29 | 2005-11-04 | Marie Madeleine Jeannet Gagnon | Traitement medical destine a faciliter la perte de poids et l'affinement localise (communement appele "cellulite") |
WO2006105455A2 (fr) * | 2005-03-31 | 2006-10-05 | Phase 2 Discovery | Methodes de traitement utilisant certains derives de melatonine |
WO2006133543A1 (fr) * | 2005-06-17 | 2006-12-21 | Everslim Formulations Ltd. | Suppléments alimentaires pour perte de poids, énergie durant la journée et relaxation la nuit |
Non-Patent Citations (6)
Title |
---|
FILE S E: "Effects of benzodiazepines and naloxone on food intake and food preference in the rat", APPETITE 1980 UNITED KINGDOM, vol. 1, no. 3, 1980, pages 215 - 224, XP009085582 * |
GADDE KISHORE M ET AL: "Bupropion treatment of olanzapine-associated weight gain - An open-label, prospective trial", JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, vol. 26, no. 4, August 2006 (2006-08-01), pages 409 - 413, XP009085605, ISSN: 0271-0749 * |
GRIMM V E ET AL: "THE EFFECTS OF CHRONIC DIAZEPAM TREATMENT ON BODY WEIGHT AND FOOD INTAKE IN RATS", INTERNATIONAL JOURNAL OF NEUROSCIENCE, vol. 18, no. 1-2, 1983, pages 127 - 136, XP009085584, ISSN: 0020-7454 * |
MCLAUGHLIN C ET AL: "CHOLECYSTOKININ AMPHETAMINE AND DIAZEPAM AND FEEDING IN LEAN AND OBESE ZUCKER RATS", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, vol. 10, no. 1, 1979, pages 87 - 94, XP002438687, ISSN: 0091-3057 * |
TEWS J K: "DIETARY GABA DECREASES BODY WEIGHT OF GENETICALLY OBESE MICE", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 29, no. 24, 14 December 1981 (1981-12-14), pages 2535 - 2542, XP001098279, ISSN: 0024-3205 * |
YUTRZENKA G J ET AL: "Substitution of temazepam and midazolam in pentobarbital-dependent rats.", PHYSIOLOGY & BEHAVIOR JUL 1989, vol. 46, no. 1, July 1989 (1989-07-01), pages 55 - 60, XP002438686, ISSN: 0031-9384 * |
Also Published As
Publication number | Publication date |
---|---|
WO2007079317A2 (fr) | 2007-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007061874A3 (fr) | Procedes et compositions utilises dans le traitement du cancer | |
WO2007064945A3 (fr) | Therapies contre le cancer et compositions pharmaceutiques utilisees dans ces therapies | |
WO2006083971A3 (fr) | Anticorps dr5 et utilisations de ceux-ci | |
WO2007064872A3 (fr) | Composes de l'uree utilises dans le traitement du cancer | |
WO2009129246A3 (fr) | Compositions et leurs procédés de préparation et d'utilisation | |
WO2009020802A3 (fr) | Traitement de l'obésité | |
WO2008039390A3 (fr) | Compositions et procédés pour améliorer la réponse immunitaire à l'aide des chitosanes | |
WO2007011962A3 (fr) | Traitement du cancer | |
WO2008150530A3 (fr) | Molécules de liaison de cripto | |
WO2007059202A3 (fr) | Derives de pyrazolyluree utilisables dans le traitement du cancer | |
WO2008100805A3 (fr) | Anticorps anti-robo4 et utilisations de ceux-ci | |
WO2009043051A3 (fr) | Molécules se fixant au cd23 et leurs méthodes d'utilisation | |
IL186458A0 (en) | Skin enrichment using coq10 as the delivery system | |
WO2006077471A3 (fr) | Therapies combinees ciblant de multiples recepteurs toll, et leur utilisation | |
WO2007022385A3 (fr) | Molécules se liant au cxcr4 | |
BRPI0812889A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com a disfunção de glutamato em um animal. | |
WO2008003007A3 (fr) | Compositions et procédés destinés au traitement d'infections parasitaires | |
WO2005097132A3 (fr) | Procedes de traitement utilisant l'eszopiclone | |
WO2007143086A3 (fr) | Procédé d'administration | |
WO2007053512A3 (fr) | Nouveaux domaines de transduction de protéines et leurs utilisations | |
MY159514A (en) | Composition comprising 1, 3/1, 6 beta glucan for reducing weight | |
WO2007146983A3 (fr) | Compositions et procédés destinés au traitement de maladies | |
ZA200903837B (en) | Use of 3-Alpha-androstanediol, optionally in combination with A-5-HT1A agonist, in the treatment of sexual dysfunction | |
WO2009150255A3 (fr) | Marqueurs destinés à prédire la réponse et la survie de patients traités anti-egfr | |
WO2007110384A3 (fr) | Tube rempli d'une mousse a cellules ouvertes de resine de melamine/formaldehye et son utilisation en tant que filtre ou melangeur statique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06849007 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06849007 Country of ref document: EP Kind code of ref document: A2 |